{ "labelLang" : "hun", "responseDate" : "2024-03-28 17:04", "content" : { "otype" : "JournalArticle", "mtid" : 32243251, "status" : "APPROVED", "published" : true, "comment" : "Export Date: 10 October 2022 \n CODEN: JPPRE \n Correspondence Address: Barvian, C.K.; Saint John Fisher CollegeUnited States; email: ckb08350@sjfc.edu", "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2023-10-17T09:38:21.487+0000", "lastModified" : "2023-04-14T07:03:56.088+0000", "created" : "2021-09-27T09:51:48.137+0000", "creator" : { "otype" : "Admin", "mtid" : 10074555, "link" : "/api/admin/10074555", "label" : "Molnár-Taga Márta (SE_AOK_Negegeszsegtan_Admin5_MTM, admin)", "familyName" : "Molnár-Taga", "givenName" : "Márta", "published" : true, "snippet" : true }, "lastDuplumOK" : "2024-03-18T12:06:28.666+0000", "lastDuplumSearch" : "2024-03-18T12:06:28.666+0000", "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000059, "link" : "/api/subtype/10000059", "label" : "Szakcikk (Folyóiratcikk)", "name" : "Szakcikk", "nameEng" : "Article", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 101, "published" : true, "oldId" : 10000059, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Barvian, C.K.", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 97681384, "link" : "/api/authorship/97681384", "label" : "Barvian, C.K. ✉", "listPosition" : 1, "share" : 0.5, "first" : true, "last" : false, "corresponding" : true, "familyName" : "Barvian", "givenName" : "C.K.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 97681385, "link" : "/api/authorship/97681385", "label" : "Cipriano, G.", "listPosition" : 2, "share" : 0.5, "first" : false, "last" : true, "corresponding" : false, "familyName" : "Cipriano", "givenName" : "G.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "How Low Can You Go? Safety and Efficacy of Sodium-Glucose Cotransporter Inhibitors in Decreased Renal Function", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 19402313, "link" : "/api/publicationidentifier/19402313", "label" : "DOI: 10.1177/08971900211039707", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1177/08971900211039707", "realUrl" : "https://doi.org/10.1177/08971900211039707", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 19402314, "link" : "/api/publicationidentifier/19402314", "label" : "WoS: 000687818200001", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000687818200001", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/000687818200001", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 19402312, "link" : "/api/publicationidentifier/19402312", "label" : "Scopus: 85113410612", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85113410612", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85113410612", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 20688540, "link" : "/api/publicationidentifier/20688540", "label" : "PubMed: 34425694", "source" : { "otype" : "PlainSource", "mtid" : 17, "link" : "/api/publicationsource/17", "label" : "PubMed", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "PubMed", "nameEng" : "PubMed", "linkPattern" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract", "publiclyVisible" : true, "published" : true, "oldId" : 17, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "34425694", "realUrl" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34425694&dopt=Abstract", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 10045897, "link" : "/api/journal/10045897", "label" : "JOURNAL OF PHARMACY PRACTICE 0897-1900 1531-1937", "pIssn" : "0897-1900", "eIssn" : "1531-1937", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 10045897, "snippet" : true }, "volume" : "36", "issue" : "2", "firstPage" : "429", "lastPage" : "444", "firstPageOrInternalIdForSort" : "429", "pageLength" : 16, "publishedYear" : 2023, "abstractText" : "Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of medications primarily used as either monotherapy or add-on therapy in those with type 2 diabetes. Given the mechanism of SGLT2 inhibitors, a renal dose adjustment or glomerular filtration rate cutoff in which it should be avoided due to decreased efficacy is recommended. However, studies have shown that these agents may possess renal benefits through decreasing serum glucose levels as well as decreasing intraglomerular pressure and albuminuria. The safety and benefits of SGLT2 inhibitors in patients with decreased renal function is an area of uncertainty. © The Author(s) 2021.", "keywords" : [ { "otype" : "Keyword", "mtid" : 1014819, "link" : "/api/keyword/1014819", "label" : "renal function", "published" : true, "oldId" : 1014819, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1527283, "link" : "/api/keyword/1527283", "label" : "SGLT2 inhibitors", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1527701, "link" : "/api/keyword/1527701", "label" : "sodium-glucose cotransporter 2 inhibitors", "published" : true, "snippet" : true } ], "digital" : true, "printed" : true, "sourceYear" : 2021, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2023-10-17", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 6, "citedCount" : 6, "ratings" : [ { "otype" : "SjrRating", "mtid" : 11406820, "link" : "/api/sjrrating/11406820", "label" : "sjr:Q2 (2023) Scopus - Pharmacy JOURNAL OF PHARMACY PRACTICE 0897-1900 1531-1937", "listPos" : 15, "rankValue" : 0.49, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 3611, "link" : "/api/classificationexternal/3611", "label" : "Scopus - Pharmacy", "published" : true, "oldId" : 3611, "snippet" : true }, "ranking" : "Q2", "calculation" : "FROM_LAST_YEAR", "published" : true, "snippet" : true } ], "ratingsForSort" : "Q2", "references" : [ { "otype" : "Reference", "mtid" : 23654714, "link" : "/api/reference/23654714", "label" : "1. Düsing, R., Mega clinical trials which have shaped the RAS intervention clinical practice (2016) Ther Adv Cardiovasc Dis, 10 (3), pp. 133-150", "listPosition" : 1, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654713, "link" : "/api/reference/23654713", "label" : "2. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease (2020) Kidney Int, 98 (4S), p. S8", "listPosition" : 2, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654712, "link" : "/api/reference/23654712", "label" : "3. [about 2 screens]. Available from", "listPosition" : 3, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654711, "link" : "/api/reference/23654711", "label" : "4. 2021 Mar 24 [cited 2021 Apr 5]", "listPosition" : 4, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654710, "link" : "/api/reference/23654710", "label" : "5. (2000), https://clinicaltrials.gov/ct2/show/NCT03982381, Bethesda, MD, National Library of Medicine (US), Identifier NCT03982381, SGLT2 inhibitor or metformin as standard treatment of early stage type 2 diabetes (SMARTEST)", "listPosition" : 5, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654709, "link" : "/api/reference/23654709", "label" : "6. [about 2 screens]. Available from", "listPosition" : 6, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654708, "link" : "/api/reference/23654708", "label" : "7. 2021 Mar 30 [cited 2021 Apr 5]", "listPosition" : 7, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654707, "link" : "/api/reference/23654707", "label" : "8. (2000), https://clinicaltrials.gov/ct2/show/NCT03717194, Bethesda, MD, National Library of Medicine (US), Identifier NCT03717194, Effect of ertugliflozin on cardiac function diabetes (ERTU-GLS)", "listPosition" : 8, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654706, "link" : "/api/reference/23654706", "label" : "9. [about 2 screens]. Available from", "listPosition" : 9, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654705, "link" : "/api/reference/23654705", "label" : "10. 2021 Mar 9 [cited 2021 Apr 5]", "listPosition" : 10, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654704, "link" : "/api/reference/23654704", "label" : "11. (2000), https://clinicaltrials.gov/ct2/show/NCT03619213, Bethesda, MD, National Library of Medicine (US), Identifier NCT03619213, Dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure (DELIVER)", "listPosition" : 11, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654703, "link" : "/api/reference/23654703", "label" : "12. [about 2 screens]. Available from", "listPosition" : 12, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654702, "link" : "/api/reference/23654702", "label" : "13. 2021 Mar 24 [cited 2021 Apr 5]", "listPosition" : 13, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654701, "link" : "/api/reference/23654701", "label" : "14. (2000), https://clinicaltrials.gov/ct2/show/NCT03057951, Bethesda, MD, National Library of Medicine (US), Identifier NCT03057951, Empagliflozin outcome trial patients with chronic heart failure with preserved ejection fraction (EMPEROR-Preserved)", "listPosition" : 14, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654700, "link" : "/api/reference/23654700", "label" : "15. Erythropoulou-Kaltsidou, A., Polychronopoulos, G., Tziomalos, K., Sodium-glucose co-transporter 2 inhibitors and fracture risk (2020) Diabetes Ther, 11 (1), pp. 7-14", "listPosition" : 15, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654699, "link" : "/api/reference/23654699", "label" : "16. cited 2021 Apr 3]. Available from", "listPosition" : 16, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654698, "link" : "/api/reference/23654698", "label" : "17. FDA Removed Boxed Warning about Risk of Leg and Foot Amputations for the Diabetes Medicine Canagliflozin (Invokana, Invokamet, Invokamet XR), , https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin, [revised 2020 Sep 9", "listPosition" : 17, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654697, "link" : "/api/reference/23654697", "label" : "18. (2017) Steglatro [Package Insert], , Whitehouse Station, NJ, Merck & Co., Inc", "listPosition" : 18, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654696, "link" : "/api/reference/23654696", "label" : "19. Packer, M., Anker, S.D., Butler, J., Cardiovascular and renal outcomes with empagliflozin in heart failure (2020) Engl J Med, 383, pp. 1413-1424", "listPosition" : 19, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654695, "link" : "/api/reference/23654695", "label" : "20. McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Dapagliflozin in patients with heart failure and reduced ejection fraction (2019) Engl J Med, 381 (21), pp. 1995-2008", "listPosition" : 20, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654694, "link" : "/api/reference/23654694", "label" : "21. Wiviott, S., Raz, I., Bonaca, M., Dapagliflozin and cardiovascular outcomes in type 2 diabetes (2019) Engl J Med, 380 (4), pp. 347-357", "listPosition" : 21, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654693, "link" : "/api/reference/23654693", "label" : "22. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021 (2021) Diabetes Care, 44, pp. S111-S124", "listPosition" : 22, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654692, "link" : "/api/reference/23654692", "label" : "23. Rabizadeh, S., Nakhjavani, M., Esteghamati, A., Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review (2019) Int J Endocrinol Metab, 17 (2), p. e84353", "listPosition" : 23, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654691, "link" : "/api/reference/23654691", "label" : "24. Cannon, C.P., Pratley, R., Dagogo-Jack, S., Cardiovascular outcomes with ertugliflozin in type 2 diabetes (2020) Engl J Med, 383, pp. 1425-1435", "listPosition" : 24, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654690, "link" : "/api/reference/23654690", "label" : "25. Perkovic, V., Jardine, M.J., Neal, B., Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (2019) Engl J Med, 380 (24), pp. 2295-2306", "listPosition" : 25, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654689, "link" : "/api/reference/23654689", "label" : "26. Neal, B., Perkovic, V., Mahaffey, K.W., Canagliflozin and cardiovascular and renal events in type 2 diabetes (2017) Engl J Med, 377 (7), pp. 644-657", "listPosition" : 26, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654688, "link" : "/api/reference/23654688", "label" : "27. Zinman, B., Wanner, C., Lachin, J., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (2015) Engl J Med, 373 (22), pp. 2117-2128", "listPosition" : 27, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654687, "link" : "/api/reference/23654687", "label" : "28. Microvascular complications and foot care: Standards of Medical Care in Diabetes—2021 (2021) Diabetes Care, 44, pp. S151-S167", "listPosition" : 28, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654686, "link" : "/api/reference/23654686", "label" : "29. Fioretto, P., Zambon, A., Rossato, M., SGLT2 inhibitors and the diabetic kidney (2016) Diabetes Care, 39 (2), pp. 165-171", "listPosition" : 29, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654685, "link" : "/api/reference/23654685", "label" : "30. Heerspink, H.J.L., Stafánsson, B.V., Correa-Rotter, R., Dapagliflozin in patients with chronic kidney disease (2020) Engl J Med, 383, pp. 1436-1446", "listPosition" : 30, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654684, "link" : "/api/reference/23654684", "label" : "31. (2014) Farxiga [Package Insert], , Princeton, NJ, Bristol-Myers Squibb Company", "listPosition" : 31, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654683, "link" : "/api/reference/23654683", "label" : "32. (2016) Jardiance [Package Insert], , Ridgefield, CT, Boehringer Pharmaceuticals, Inc", "listPosition" : 32, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654682, "link" : "/api/reference/23654682", "label" : "33. (2013) Invokana [Package Insert], , Titusville, NJ, Janssen Ortho LLC", "listPosition" : 33, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654681, "link" : "/api/reference/23654681", "label" : "34. Cowart, S.L., Stachura, M.E., Glucosuria (1990) Clinical Methods: The History, Physical, and Laboratory Examinations, pp. 653-657. , Walker H.K., Hall W.D., Hurst J.W., (eds), Boston, MA, Butterworth, In:, eds", "listPosition" : 34, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 23654680, "link" : "/api/reference/23654680", "label" : "35. Kalra, S., Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology (2014) Diabetes Ther, 5 (2), pp. 355-366", "listPosition" : 35, "published" : false, "snippet" : true } ], "hasCitationDuplums" : false, "userChangeableUntil" : "2022-01-19T09:12:02.249+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 13, "ownerInstituteCount" : 71, "directInstituteCount" : 0, "authorCount" : 2, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/32243251", "label" : "Barvian C.K. et al. How Low Can You Go? Safety and Efficacy of Sodium-Glucose Cotransporter Inhibitors in Decreased Renal Function. (2023) JOURNAL OF PHARMACY PRACTICE 0897-1900 1531-1937 36 2 429-444", "template" : "